<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02169115</url>
  </required_header>
  <id_info>
    <org_study_id>CIGE025EDE17T</org_study_id>
    <secondary_id>2011-005615-87</secondary_id>
    <nct_id>NCT02169115</nct_id>
  </id_info>
  <brief_title>Urticaria Facticia Treatment With Omalizumab (UFO)</brief_title>
  <acronym>UFO</acronym>
  <official_title>Double-blind, Placebo-controlled 12-week, Parallel-group Study With a 6 Weeks Follow up Period to Demonstrate Efficacy and Safety of Subcutaneous Omalizumab in Patients With Urticaria Factitia Refractory to Standard Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urticaria is a very frequent skin condition characterized by transient wheal and flare type&#xD;
      skin reactions associated with severe pruritus. In Europe alone, more than 5 million patients&#xD;
      are thought to suffer from persisting urticaria symptoms, which either occur spontaneously,&#xD;
      i.e. in chronic spontaneous urticaria (CSU), or as a result of environmental physical stimuli&#xD;
      such as friction, pressure, UV irradiation or cold (physical urticaria). Urticaria factitia&#xD;
      (also known as dermographic urticaria and symptomatic dermographism) is characterized by&#xD;
      whealing and itching following a minor stroking pressure, rubbing or scratching of the skin.&#xD;
      The majority of patients with urticaria factitia benefits from treatment with nonsedating&#xD;
      antihistamines. Some patients, however, do not achieve adequate symptom control even with&#xD;
      updosing of antihistamines and may suffer from substantial quality of life impairment . Since&#xD;
      even very minor stroking of the skin can lead to the development of wheals and severe&#xD;
      itching, these patients are for example limited in their choice of clothing and are impaired&#xD;
      in their social interaction and partnership.&#xD;
&#xD;
      In all patients with a history of wheals after stroking of the skin, a provocation test&#xD;
      should be performed. This can be done by stroking of the skin lightly with a smooth blunt&#xD;
      object (e.g. the tip of a closed ball point pen or a wooden spatula) or a purpose-built&#xD;
      instrument, known as a dermographometer. For the diagnosis of symptomatic dermographism, the&#xD;
      smooth blunt object should be held perpendicular to the skin and should be used to apply a&#xD;
      light stroking pressure to the skin of the upper back or volar forearm. The reaction is&#xD;
      considered positive in patients who show a weal response and report pruritus at the site of&#xD;
      provocation.&#xD;
&#xD;
      Patients with a positive test reaction should be evaluated for individual pressure&#xD;
      thresholds. For this purpose a provocation device (FricTest) has been developed that allows&#xD;
      for reproducible and standardized threshold testing. Threshold testing enables physicians to&#xD;
      assess disease severity and treatment response more precisely.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo</measure>
    <time_frame>70 days</time_frame>
    <description>Patients receive provocation test by FricTest (standardized stroking of the skin). FricTest ratings are from 0 (no wheal development to the longest pin) to 4 (wheal development to all four pins). The development of wheals within 30 minutes after provocation is monitored.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Assess the Effects of Omalizumab in Urticaria Factitia Patients on Quality of Life</measure>
    <time_frame>70 days</time_frame>
    <description>Change in quality of life scores assessed by Dermatology Life Quality Index (DLQI) and UF specific life quality questions from baseline to day 70 after treatment with omalizumab compared to placebo. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. The DLQI can also be expressed as a percantage of the maximum possible score of 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Effects of Omalizumab in UF Patients on Number of Symptom Free Days</measure>
    <time_frame>70 days</time_frame>
    <description>Change in number of symptom free days as assessed by a patient diary from baseline to day 70 after treatment with omalizumab compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Effects of Omalizumab in UF Patients on Physician Global Assessment of Disease Severity</measure>
    <time_frame>70 days</time_frame>
    <description>Change in physician global assessment of disease severity assessed by visual analogue scale by a physician from baseline to day 70 after treatment with omalizumab compared to placebo. VAS are measuring instruments designed to document the characteristics of disease-related symptom severity in individual patients. The scale ranges from a minimum of 0 and a maximum of 10. The higher the score, the worse the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Effects of Omalizumab in UF Patients on Patient Global Assessment of Disease Severity</measure>
    <time_frame>70 days</time_frame>
    <description>Change in patient global assessment of disease severity assessed by visual analogue scale by the patient from baseline to day 70 after treatment with omalizumab compared to placebo. VAS are measuring instruments designed to document the characteristics of disease-related symptom severity in individual patients. The scale ranges from a minimum of 0 and a maximum of 10. The higher the score, the worse the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess Long-term Effects of Omalizumab in UF Patients</measure>
    <time_frame>112 days</time_frame>
    <description>To assess long-term effects of omalizumab in UF patients, change in friction thresholds from day 70 (week 10) to day 112 (week 16) will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events and Adverse Events</measure>
    <time_frame>112 days</time_frame>
    <description>Safety of patients treated with omalizumab: This includes physical examination, routine safety laboratory assessments, vital signs and adverse event reporting</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Symptomatic Dermographism</condition>
  <arm_group>
    <arm_group_label>Omalizumab 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Omalizumab 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>150mg, s.c., every 4 weeks</description>
    <arm_group_label>Omalizumab 150mg</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>300mg, s.c., every 4 weeks</description>
    <arm_group_label>Omalizumab 300mg</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, s.c., every 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (18-75 years)&#xD;
&#xD;
          -  Informed consent signed and dated&#xD;
&#xD;
          -  Able to read, understand and willing to sign the informed consent form and abide with&#xD;
             study procedures&#xD;
&#xD;
          -  Diagnosis of UF lasting for at least 6 months&#xD;
&#xD;
          -  Willing, committed and able to return for all clinic visits and complete all&#xD;
             study-related procedures, including willingness to have SC injections administered by&#xD;
             a qualified person&#xD;
&#xD;
          -  In females of childbearing potential: Negative pregnancy test; females willing to use&#xD;
             highly effective contraception (Pearl-Index &lt; 1). A woman will be considered not of&#xD;
             childbearing potential if she is post-menopausal for greater than two years or&#xD;
             surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy)&#xD;
&#xD;
          -  No participation in other clinical trials 4 weeks before and after participation in&#xD;
             this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with acute urticaria&#xD;
&#xD;
          -  Concurrent/ongoing treatment with immunosuppressives (e.g. systemic steroids,&#xD;
             cyclosporine, methotrexate, dapsone or others) within 4 weeks or 5 half lives prior to&#xD;
             day 0, whichever is longer&#xD;
&#xD;
          -  Significant medical condition rendering the patient immunocompromised or not suitable&#xD;
             for a clinical trial&#xD;
&#xD;
          -  Significant concomitant illness that would adversely affect the subject's&#xD;
             participation or evaluation in this study&#xD;
&#xD;
          -  History of malignancies within five years prior to screening other than a successfully&#xD;
             treated non-metastatic cutaneous, basal, or squamous cell carcinoma and/or in situ&#xD;
             cancer&#xD;
&#xD;
          -  Presence of clinically significant laboratory abnormalities&#xD;
&#xD;
          -  Lactating females or pregnant females&#xD;
&#xD;
          -  Subjects for whom there is concern about compliance with the protocol procedures&#xD;
&#xD;
          -  Any medical condition which, in the opinion of the Investigator, would interfere with&#xD;
             participation in the study or place the subject at risk&#xD;
&#xD;
          -  History of substance abuse (drug or alcohol) or any other factor (e.g., serious&#xD;
             psychiatric condition) within the last 5 years that could limit the subject's ability&#xD;
             to comply with study procedures&#xD;
&#xD;
          -  Subjects who are detained officially or legally to an official institute&#xD;
&#xD;
          -  Previous use of omalizumab within the last 6 months&#xD;
&#xD;
          -  Intake of antihistamines or leukotriene antagonists within 4 days prior to visit 1&#xD;
&#xD;
          -  Intake of oral corticosteroids within 14 days prior to visit 1&#xD;
&#xD;
          -  Use of depot corticosteroids or chronic systemic corticosteroids within 21 days before&#xD;
             beginning of the study&#xD;
&#xD;
          -  Known hypersensitivity to any ingredients, including excipients (sucrose, histidine,&#xD;
             polysorbate 20) of the study medication or drugs related to omalizumab (e.g.:&#xD;
             monoclonal antibodies, polyclonal gammaglobulin)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Metz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Dermatology Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology University Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2014</study_first_posted>
  <results_first_submitted>October 28, 2015</results_first_submitted>
  <results_first_submitted_qc>December 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2016</results_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Martin Metz</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omalizumab 150mg</title>
          <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Omalizumab 300mg</title>
          <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo: Placebo, s.c., every 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omalizumab 150mg</title>
          <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Omalizumab 300mg</title>
          <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo: Placebo, s.c., every 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo</title>
        <description>Patients receive provocation test by FricTest (standardized stroking of the skin). FricTest ratings are from 0 (no wheal development to the longest pin) to 4 (wheal development to all four pins). The development of wheals within 30 minutes after provocation is monitored.</description>
        <time_frame>70 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab 150mg</title>
            <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Omalizumab 300mg</title>
            <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo, s.c., every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo</title>
          <description>Patients receive provocation test by FricTest (standardized stroking of the skin). FricTest ratings are from 0 (no wheal development to the longest pin) to 4 (wheal development to all four pins). The development of wheals within 30 minutes after provocation is monitored.</description>
          <units>wheal development up to four pins</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="1.7"/>
                    <measurement group_id="O2" value="-2.0" spread="1.8"/>
                    <measurement group_id="O3" value="-0.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.7</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.8</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Effects of Omalizumab in Urticaria Factitia Patients on Quality of Life</title>
        <description>Change in quality of life scores assessed by Dermatology Life Quality Index (DLQI) and UF specific life quality questions from baseline to day 70 after treatment with omalizumab compared to placebo. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. The DLQI can also be expressed as a percantage of the maximum possible score of 30.</description>
        <time_frame>70 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab 150mg</title>
            <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Omalizumab 300mg</title>
            <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: s.c., every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Effects of Omalizumab in Urticaria Factitia Patients on Quality of Life</title>
          <description>Change in quality of life scores assessed by Dermatology Life Quality Index (DLQI) and UF specific life quality questions from baseline to day 70 after treatment with omalizumab compared to placebo. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. The DLQI can also be expressed as a percantage of the maximum possible score of 30.</description>
          <units>Dermatology quality of life score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.611" spread="1.234"/>
                    <measurement group_id="O2" value="-5.579" spread="1.478"/>
                    <measurement group_id="O3" value="-2.316" spread="0.949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Effects of Omalizumab in UF Patients on Number of Symptom Free Days</title>
        <description>Change in number of symptom free days as assessed by a patient diary from baseline to day 70 after treatment with omalizumab compared to placebo</description>
        <time_frame>70 days</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab 150mg</title>
            <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Omalizumab 300mg</title>
            <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: s.c., every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Effects of Omalizumab in UF Patients on Number of Symptom Free Days</title>
          <description>Change in number of symptom free days as assessed by a patient diary from baseline to day 70 after treatment with omalizumab compared to placebo</description>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Effects of Omalizumab in UF Patients on Physician Global Assessment of Disease Severity</title>
        <description>Change in physician global assessment of disease severity assessed by visual analogue scale by a physician from baseline to day 70 after treatment with omalizumab compared to placebo. VAS are measuring instruments designed to document the characteristics of disease-related symptom severity in individual patients. The scale ranges from a minimum of 0 and a maximum of 10. The higher the score, the worse the outcome.</description>
        <time_frame>70 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab 150mg</title>
            <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Omalizumab 300mg</title>
            <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo, s.c., every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Effects of Omalizumab in UF Patients on Physician Global Assessment of Disease Severity</title>
          <description>Change in physician global assessment of disease severity assessed by visual analogue scale by a physician from baseline to day 70 after treatment with omalizumab compared to placebo. VAS are measuring instruments designed to document the characteristics of disease-related symptom severity in individual patients. The scale ranges from a minimum of 0 and a maximum of 10. The higher the score, the worse the outcome.</description>
          <units>units on a sclae</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" spread="3.63"/>
                    <measurement group_id="O2" value="28.33" spread="6.23"/>
                    <measurement group_id="O3" value="40.32" spread="6.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Effects of Omalizumab in UF Patients on Patient Global Assessment of Disease Severity</title>
        <description>Change in patient global assessment of disease severity assessed by visual analogue scale by the patient from baseline to day 70 after treatment with omalizumab compared to placebo. VAS are measuring instruments designed to document the characteristics of disease-related symptom severity in individual patients. The scale ranges from a minimum of 0 and a maximum of 10. The higher the score, the worse the outcome.</description>
        <time_frame>70 days</time_frame>
        <population>Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab 150mg</title>
            <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Omalizumab 300mg</title>
            <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo, s.c., every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Effects of Omalizumab in UF Patients on Patient Global Assessment of Disease Severity</title>
          <description>Change in patient global assessment of disease severity assessed by visual analogue scale by the patient from baseline to day 70 after treatment with omalizumab compared to placebo. VAS are measuring instruments designed to document the characteristics of disease-related symptom severity in individual patients. The scale ranges from a minimum of 0 and a maximum of 10. The higher the score, the worse the outcome.</description>
          <population>Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess Long-term Effects of Omalizumab in UF Patients</title>
        <description>To assess long-term effects of omalizumab in UF patients, change in friction thresholds from day 70 (week 10) to day 112 (week 16) will be assessed</description>
        <time_frame>112 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab 150mg</title>
            <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Omalizumab 300mg</title>
            <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo, s.c., every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess Long-term Effects of Omalizumab in UF Patients</title>
          <description>To assess long-term effects of omalizumab in UF patients, change in friction thresholds from day 70 (week 10) to day 112 (week 16) will be assessed</description>
          <units>Fric Test grades</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0556" spread="1.39209"/>
                    <measurement group_id="O2" value="-0.8421" spread="1.77210"/>
                    <measurement group_id="O3" value="-0.8333" spread="1.50489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events and Adverse Events</title>
        <description>Safety of patients treated with omalizumab: This includes physical examination, routine safety laboratory assessments, vital signs and adverse event reporting</description>
        <time_frame>112 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab 150mg</title>
            <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Omalizumab 300mg</title>
            <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo, s.c., every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events and Adverse Events</title>
          <description>Safety of patients treated with omalizumab: This includes physical examination, routine safety laboratory assessments, vital signs and adverse event reporting</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Omalizumab 150mg</title>
          <description>Omalizumab: 150mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Omalizumab 300mg</title>
          <description>Omalizumab: 300mg, s.c., every 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo: Placebo, s.c., every 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Unspecified renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Acute cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Martin Metz</name_or_title>
      <organization>Charité- Dpt. of Dermatology and Allergy</organization>
      <phone>+49 30 450 518 159</phone>
      <email>martin.metz@charite.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

